2026-06-08T11:07:23Zhttps://docta.ucm.es/rest/oai/request

oai:docta.ucm.es:20.500.14352/1204252025-05-23T00:12:58Zcom_20.500.14352_14col_20.500.14352_15

00925njm 22002777a 4500 dc Więckowska, Anna author Szałaj, Natalia author Góral, Izabella author Bucki, Adam author Latacz, Gniewomir author Kiec Kononowicz, Katarzyna author Bautista Aguilera, Òscar M author Romero Martínez, Manuel Alejandro author Ramos Alonso, Eva author Egea, Javier author Farré Alíns, Victor author González Rodríguez, Águeda author López Muñoz, Francisco author Chioua, Mourad author Marco Contelles, José Luis author 2020-11-18 Herein we report metabolic stability in human liver microsomes (HLMs), interactions with cytochrome P450 isoenzymes (CYP3A4, CYP2D6, and CYP2C9), and cytotoxicity analyses on HEK-293, HepG2, Huh7, and WTIIB cell lines of our most recent multitarget directed ligands PF9601N, ASS234, and contilisant. Based on these results, we conclude that (1) PF9601N and contilisant are metabolically stable in the HLM assay, in contrast to the very unstable ASS234; (2) CYP3A4 activity was decreased by PF9601N at all the tested concentrations and by ASS234 and contilisant only at the highest concentration; CYP2D6 activity was reduced by ASS234 at 1, 10, and 25 μM and by PF9601N at 10 and 25 μM, whereas contilisant increased its activity at the same concentrations; CYP2C9 was inhibited by the three compounds; (3) contilisant did not affect cell viability in the widest range of concentrations: up to 10 μM on HEK-293 cells, up to 30 μM on Huh7 cells, up to 50 μM on HepG2 cells, and up to 30 or 100 μM on WTIIB cells. Based on these results, we selected contilisant as a metabolically stable and nontoxic lead compound for further studies in Alzheimer's disease therapy. Więckowska, A., Szałaj, N., Góral, I., Bucki, A., Latacz, G., Kiec-Kononowicz, K., Bautista-Aguilera, Ò. M., Romero, A., Ramos, E., Egea, J., Farré Alíns, V., González-Rodríguez, Á., López-Muñoz, F., Chioua, M., & Marco-Contelles, J. (2020). In Vitro and In Silico ADME-Tox Profiling and Safety Significance of Multifunctional Monoamine Oxidase Inhibitors Targeting Neurodegenerative Diseases. ACS chemical neuroscience, 11(22), 3793–3801. https://doi.org/10.1021/acschemneuro.0c00489 1948-7193 10.1021/acschemneuro.0c00489 https://hdl.handle.net/20.500.14352/120425 https://doi.org/10.1021/acschemneuro.0c00489 33143412 In Vitro and In Silico ADME-Tox Profiling and Safety Significance of Multifunctional Monoamine Oxidase Inhibitors Targeting Neurodegenerative Diseases.